Physician
Cardiology
Dr. Michael S. Ewer, MD
|
|
Give Review
Doctor Michael S. Ewer, MD works in the field of Cardiology. Michael S. Ewer has written publications. He has 96 publications published with PubMed. The lastest paper is: 'Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration.' Michael S. Ewer, MD accepts Medicare payments and is listed with Medicare.gov.
Publications
- Mechanisms underlying trastuzumab activity are complex.
- Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Lab...
- Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically...
- Current Practices in the Management of Adverse Events Associated With Targeted Therapies for Advanced Renal Cell Carcinoma: A National Survey of Oncologists.
- Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor ...
- Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab ...
- Enigmas regarding the true extent and impact of tyrosine kinase inhibitor-related cardiotoxicity.
- Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Pl...
- Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP ...
- Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs.
- Screening for Cardiac Risk Before Anthracycline Administration: What Are The Real Benefits?
- A historical perspective of anthracycline cardiotoxicity.
- Developing a transfer center in a tertiary cancer center: streamlining access and communication to accommodate increasing demand for service.
- Cardiac dysfunction after cancer treatment.
- The integrity of authorship: doing the right thing.
- Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction.
- Long-term cardiac safety of dose-dense anthracycline therapy cannot be predicted from early ejection fraction data.
- A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health.
- Anthracycline cardiotoxicity: why are we still interested?
- Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.
- Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?
- Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?
- Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.
- Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth fact...
- Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
- Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized tr...
- Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.
- Cardiac safety of liposomal anthracyclines.
- Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.
- Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.
- A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
- Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant ther...
- Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.
- Doxorubicin-induced congestive heart failure in adults.
- A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.
- Phase II clinical trial of 4'-O-tetrahydropyranyl-adriamycin (THP-adriamycin) in recurrent squamous cell carcinoma of the head and neck.
- Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer.
- Phase I clinical investigation of homoharringtonine.
- Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
- Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity.
- 5-fluorouracil, adriamycin, and mitomycin-C (Hi-FAM) chemotherapy for adenocarcinoma of the lung.
- Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer.
- NG-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension.
- Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.
- Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience.
- Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration.
- Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
- Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
- Advance directives in the intensive care unit of a tertiary cancer center.
- Assessment of anthracycline cardiomyopathy by endomyocardial biopsy.
- Cardiac transplantation and aspergillosis.
- Late doxorubicin-associated cardiotoxicity in children. The possible role of intercurrent viral infection.
- Cardiac diastolic function in pediatric patients receiving doxorubicin.
- Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.
- Predicting loss of pulmonary function after pulmonary resection for bronchogenic carcinoma.
- Open chest resuscitation for cardiopulmonary arrest related to mechanical impairment of circulation: a report of two cases.
- Regional and overall pulmonary function changes in lung cancer. Correlations with tumor stage, extent of pulmonary resection, and patient survival.
- Noninvasive cardiac evaluation of patients receiving adriamycin-containing adjuvant chemotherapy (FAC) for stage II or III breast cancer.
- Postresection bronchopleural fistula: detection by regional ventilation-perfusion studies.
- A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin.
- Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study.
- [Early development of the stroma corneae and the pupillary membrane in man].
- Malignant cardiac fibrous histiocytomas and angiosarcomas: MR features.
- Surgical treatment of the cancer patient: preoperative assessment and perioperative medical management.
- Postoperative atrial fibrillation in cancer surgery: preoperative risks and clinical outcome.
- Cardiac emergencies in the cancer patient.
- Nodus migrans: the case of the migrating knot.
- Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update.
- Pleural and pericardial effusions in cancer patients.
- Outcome of lung cancer patients requiring mechanical ventilation for pulmonary failure.
- Coronary artery embolism following cancer chemotherapy.
- Pericardial effusion with tamponade: relief for the symptomatic patient.
- Critical cardiologic considerations in the cancer patient.
- Syncope and hypotension due to carcinoma of the breast metastatic to the carotid sinus.
- Balloon angioplasty for superior vena cava obstruction.
- Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.
- Philosophy of care, decision making, and ethical considerations.
- A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer.
- Shock: managing the septic syndrome in patients with cancer.
- Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy.
- Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?
- Characteristics of cardiac arrest in cancer patients as a predictor of survival after cardiopulmonary resuscitation.
- Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules.
- The definition of medical futility: Are we trying to define the wrong term?
- Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?
- Outcome and cost implications of cardiopulmonary resuscitation in the medical intensive care unit of a comprehensive cancer center.
- Anthracycline cardiotoxicity.
- Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.
- The anthracycline-trastuzumab interaction: Up-regulated binding may provide vital mechanistic insight.
- Is trastuzumab associated with adverse cardiac effects in patients with breast cancer?
- Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.
- Cardiotoxicity of anticancer treatments: what the cardiologist needs to know.
- Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.
- Sunitinib-related cardiotoxicity: an interdisciplinary issue.
- Cardiotoxicity profile of trastuzumab.
Doctors Specialties
- Internal Medicine
- Cardiology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- American Republic
- Blue Card PPO
- Blue Choice
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health Care
- Emblem Health
- First Health (Coventry Health Care) PPO
- GEHA
- HealthSmart
- Choice Care PPO
- Mail Handlers Benefit Plan (MHBP)
- Medical Mutual of Ohio
- Medicare MCR
- MHealth Insured
- MultiPlan PPO
- PHCS Network PPO
- National Elevator
- Old Surety Life Insurance CompanyMedicare MCR
- POMCO Group
- Principal Life
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- Wisconsin Physicians Service
Education
-
Baylor University Medical Center -
Memorial Hospital of Rhode Island -
University of Basel Faculty of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1669540142 | |
| NPPES Provider LastName | EWER | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 770304439 | |
| NPPES Provider State | TX | |
| Specialty Description | Cardiology | |
| Total Claim Count | 27.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1669540142 |
| Last Name Of The Provider | EWER |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
|
Dr. Matteethra C. Jacob, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Selby B. Oberton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jorge M. Escobar Camargo, MD |